Biomedical Catalyst: Developmental Pathway Funding Scheme (DPFS) outline: Mar 2020
Please note this opportunity is now CLOSED.
View all OPEN opportunities
体育直播站dpfs is an ongoing scheme, with outline deadlines every 4 months.
further details of open and future dpfs deadlines can be found on the for the scheme.
the dpfs scheme is a key part of our translational research strategy and supports the translation of fundamental discoveries toward benefits to human health. it funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies.
the scheme supports academically led projects whose goals are to improve prevention, diagnosis, prognosis, or treatment of significant health needs, or that focus on developing research tools that increase the efficiency of developing interventions.
projects supported by the scheme have up to four clearly defined milestones, outcomes and future plans. these help to maximise both the chance of success and the likelihood of the project attracting the downstream funding, from public or private sources, required to meet its clinical and commercial aims. the funding panels assessing the project will, if necessary, help to develop proposals and suggest enhancements.
the following activities are eligible for support:
- Developing candidate therapeutic entities (e.g. drug discovery)
- Pre-clinical testing of novel therapeutic entities
- Early-phase clinical studies of novel therapeutic entities (phases 1 and 2)
- “Repurposing” clinical studies – using existing therapies for new indications
- Developing and testing novel devices
- Developing and testing diagnostics (including biomarker validation)
individual projects can start and finish at any point along the translational pathway but would not typically progress from initial development through to phase 2 clinical testing in a single application. where there is a justified need for continued mrc support, sequential applications are encouraged.
体育直播站all disease areas (including those relevant to global health) and modalities of intervention are eligible for support from the scheme, including small molecules, peptides, antibodies, vaccines, regenerative medicine, cell and gene therapy, devices, surgical techniques and psychological approaches.
Funding to support projects whose goals are to generate the evidence needed to submit a mature, substantial, request to develop regenerative medicine therapies would be welcomed through the Research Boards体育直播站, and should be directed to the Board most appropriate to the science proposed.
体育直播站the following activities are ineligible for support:
- Fundamental or investigative research not linked to a development plan (supported by the Research Boards
- Clinical studies where the primary purpose is to investigate disease mechanism (supported by the Research Boards
- Late-phase clinical trials (supported by the and the )
- Late-phase global health trials (supported by the Global Health Trials Programme and the Joint Global Health Trials Scheme).
Please note that there is no formal limit to the total amount that can be requested in a DPFS grant – all costs should be fully justified within a proposal and the Panel will assess value for money in the context of the proposed work.
Applications including partnerships with charities or industry are encouraged where these add value to the project – for example, in terms of access to expertise, technologies, reagents or funding. Please note that industrial collaboration is not a prerequisite for application.
Applications involving collaboration with industry should adhere to the MRC Industry Collaboration Agreement guidance. The lead applicant must be the academic partner, and the MRC will meet the academic costs of the project only.
Proposals are assessed in a two-stage process. The first step involves review of an outline proposal (download the outline Case for Support form here体育直播站). Successful outline applicants are invited to submit a full application, which undergoes external peer review before a further, more detailed, review by the Panel. The total assessment time for an application submitted to MRC, from outline submission to full decision, is approximately 26 weeks.
all applicants will receive feedback from the assessment process. guidance for preparation of full proposals will be provided to successful applicants with the outline feedback.
Guidance for applicants
Both and governance and on preparation of DPFS outline proposals are available. The outline Case for Support form should be downloaded directly from this page. Applicants should also review our general guidance for applicants.
For all general enquiries, please contact the DPFS Team on DPFSandDCS@wnjrkh.icu
体育直播站if you have any specific queries about this funding scheme, please contact:
Dr Adam Babbs (Adam.Babbs@wnjrkh.icu) Phone: 01793 416414
体育直播站 Small molecules and drug (other)
Dr Charlotte Durkin (Charlotte.Durkin@wnjrkh.icu) Phone: 01793 416420
Dr Tim Ellis (Tim.Ellis@wnjrkh.icu) Phone: 07599 500153
体育直播站 Biomarkers and diagnostic
Dr Agnes Leong (Agnes.Leong@wnjrkh.icu) Phone: 0207 395 2220
体育直播站 Therapeutic devices, psychological therapies, Digital health (software development/AI tools), radiology and imaging
Dr Alex Phillips (Alexandra.Phillips@wnjrkh.icu)
Antibodies, proteins and peptide therapeutics
Dr Penny Morton (Penny.Morton@wnjrkh.icu) Phone: 0207 395 2244
体育直播站 Advanced therapeutics: vectors, gene, nucleic acid and siRNA therapies